Sophia Genetics SA (SOPH) - Total Liabilities
Based on the latest financial reports, Sophia Genetics SA (SOPH) has total liabilities worth $102.77 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sophia Genetics SA - Total Liabilities Trend (2018–2024)
This chart illustrates how Sophia Genetics SA's total liabilities have evolved over time, based on quarterly financial data. See Sophia Genetics SA (SOPH) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Sophia Genetics SA Competitors by Total Liabilities
The table below lists competitors of Sophia Genetics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jindal Worldwide Limited
NSE:JINDWORLD
|
India | Rs7.98 Billion |
|
Advancetek Enterprise Co Ltd
TW:1442
|
Taiwan | NT$6.45 Billion |
|
Denny’s Corp
NASDAQ:DENN
|
USA | $535.61 Million |
|
Sky Harbour Group Corporation
NYSE:SKYH
|
USA | $599.45 Million |
|
Beijing New Universal Science and Technology Co Ltd
SHE:300472
|
China | CN¥1.06 Billion |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
Korea | ₩137.93 Billion |
|
Zorlu Enerji Elektrik Uretim AS
IS:ZOREN
|
Turkey | TL73.98 Billion |
|
Abeona Therapeutics Inc
NASDAQ:ABEO
|
USA | $60.35 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Sophia Genetics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sophia Genetics SA (SOPH) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sophia Genetics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sophia Genetics SA (2018–2024)
The table below shows the annual total liabilities of Sophia Genetics SA from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $58.82 Million | +7.50% |
| 2023-12-31 | $54.71 Million | +25.18% |
| 2022-12-31 | $43.71 Million | -2.38% |
| 2021-12-31 | $44.77 Million | +41.66% |
| 2020-12-31 | $31.61 Million | +7.49% |
| 2019-12-31 | $29.40 Million | +34.85% |
| 2018-12-31 | $21.80 Million | -- |
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more